Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen

Biochem Pharmacol. 2015 Sep 1;97(1):89-98. doi: 10.1016/j.bcp.2015.06.021. Epub 2015 Jun 25.

Abstract

The prevalence of hyperuricemia/gout increases with aging. However, the effect of aging on function for excretion of uric acid to out of the body has not been clarified. We found that ileal uric acid clearance in middle-aged rats (11-12 months) was decreased compared with that in young rats (2 months). In middle-aged rats, xanthine oxidase (XO) activity in the ileum was significantly higher than that in young rats. Inosine-induced reactive oxygen species (ROS), which are derived from XO, also decreased ileal uric acid clearance. ROS derived from XO decreased the active homodimer level of breast cancer resistance protein (BCRP), which is a uric acid efflux transporter, in the ileum. Pre-administration of allopurinol recovered the BCRP homodimer level, resulting in the recovering ileal uric acid clearance. Moreover, we investigated the effects of ROS derived from XO on BCRP homodimer level directly in Caco-2 cells using hypoxanthine. Treatment with hypoxanthine decreased BCRP homodimer level. Treatment with hypoxanthine induced mitochondrial dysfunction, suggesting that the decreasing BCRP homodimer level might be caused by mitochondrial dysfunction. In conclusion, ROS derived from XO decrease BCRP homodimer level, resulting in suppression of function for uric acid excretion to the ileal lumen. ROS derived from XO may cause the suppression of function of the ileum for the excretion of uric acid with aging. The results of our study provide a new insight into the causes of increasing hyperuricemia/gout prevalence with aging.

Keywords: Aging; Breast cancer resistance protein; Hyperuricemia; Reactive oxygen species; Uric acid excretion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters / antagonists & inhibitors*
  • ATP-Binding Cassette Transporters / chemistry
  • ATP-Binding Cassette Transporters / genetics
  • ATP-Binding Cassette Transporters / metabolism
  • Aging*
  • Allopurinol / pharmacology
  • Allopurinol / therapeutic use
  • Animals
  • Caco-2 Cells / drug effects
  • Caco-2 Cells / metabolism
  • Dimerization
  • Enzyme Induction / drug effects
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Gout Suppressants / pharmacology
  • Gout Suppressants / therapeutic use
  • Humans
  • Hyperuricemia / chemically induced
  • Hyperuricemia / metabolism
  • Hyperuricemia / prevention & control
  • Hypoxanthine / pharmacology
  • Ileum / drug effects
  • Ileum / growth & development
  • Ileum / metabolism
  • Inosine / toxicity
  • Intestinal Elimination / drug effects
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / growth & development
  • Intestinal Mucosa / metabolism*
  • Male
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Mitochondria / metabolism
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / chemistry
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • Rats, Wistar
  • Reactive Oxygen Species / agonists
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism*
  • Uric Acid / metabolism*
  • Xanthine Oxidase / antagonists & inhibitors
  • Xanthine Oxidase / chemistry
  • Xanthine Oxidase / metabolism*

Substances

  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters
  • Abcg2 protein, rat
  • Enzyme Inhibitors
  • Gout Suppressants
  • Neoplasm Proteins
  • Reactive Oxygen Species
  • Uric Acid
  • Hypoxanthine
  • Inosine
  • Allopurinol
  • Xanthine Oxidase